Understanding how cells transform into specialized types during human development is a central challenge in biology. This ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

The key is the ligand — that’s the general word for whatever chemical messenger ... Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1, binding ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy. The notice was issued on Tuesday ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under ...

The international team describes their results and the underlying molecular mechanism in Cell Metabolism. Ergothioneine is a natural compound found in certain fungi such as oyster or shiitake ...

The Royal Society of Chemistry has agreed a new three-year Open Access publishing agreement with Couperin, a consortium of French Higher Education and Research establishments.

Close to 2.3 million seniors in Medicare are using the semaglutide medications, branded as Ozempic, Rybelsus and Wegovy by Novo Nordisk. Medicare says that the drug added up to more than $14 ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

Novo’s booming semaglutide franchise for diabetes and obesity is the standout inclusion in this year’s list. The U.S. Department of Health and Human Services unveiled the list of 15 drugs Friday.